文献速递妇科

MiR-29c下调肿瘤表达的B7-H3介导卵巢癌中抗肿瘤NK细胞功能

MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-04-17

本研究探讨卵巢癌中B7-H3调控NK细胞增殖与功能的机制。通过人卵巢肿瘤组织和细胞系检测B7-H3表达,建立B7-H3敲除细胞系,用LDH释放实验和流式细胞术测NK细胞毒性,并分析糖酵解及荧光素酶报告实验验证miR-29c直接调控B7-H3,最后进行体内实验。结果显示肿瘤表达的B7-H3在体外和体内抑制NK细胞功能,与卵巢癌细胞糖酵解相关;B7-H3阻断延长SKOV3荷瘤小鼠生存;miR-29c在体外通过直接靶向B7-H3改善NK细胞抗肿瘤效果,但体内未观察到。

要点

  • 肿瘤表达的B7-H3在体外和体内抑制卵巢癌NK细胞功能。
  • B7-H3阻断延长SKOV3荷瘤小鼠生存。
  • miR-29c体外直接靶向B7-H3改善NK细胞抗肿瘤效果,体内未观察到。

核心结论

  • miR-29c下调B7-H3以抑制NK细胞耗竭并与糖酵解相关,提示NK细胞可能是卵巢癌抗B7-H3治疗的新靶点。

研究设计与样本

  • 研究检测人卵巢肿瘤组织和细胞系中B7-H3的蛋白和mRNA表达。
  • 建立B7-H3敲除细胞系,用LDH释放实验和流式细胞术测NK细胞毒性。
  • 用糖酵解压力测试、葡萄糖消耗实验和Western-blot分析B7-H3对糖酵解及糖酵解相关蛋白的调控。
  • 用荧光素酶报告实验确认miR-29c对B7-H3的直接调控,并进行体内实验。

主要发现

  • 肿瘤表达的B7-H3在体外和体内抑制NK细胞功能,并与卵巢癌细胞糖酵解相关。
  • B7-H3阻断延长SKOV3荷瘤小鼠生存。
  • miR-29c在体外通过直接靶向B7-H3改善NK细胞抗肿瘤效果,但体内未观察到。

临床怎么用

  • B7-H3阻断在SKOV3荷瘤小鼠中延长生存,提示抗B7-H3治疗可能用于卵巢癌。
  • NK细胞可能是卵巢癌抗B7-H3治疗的新靶点。

局限性

  • miR-29c改善NK细胞抗肿瘤效果仅在体外观察到,体内未观察到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: B7-H3 is a member of the B7 family of immune checkpoint molecule. Although B7-H3 has been shown to regulate T cell-mediated peripheral immune response, whether it also correlated with NK cell exhaustion in ovarian cancer remains unclear. The purpose of this study was to explore the mechanism of B7-H3 regulating NK-cell proliferation and function. MATERIAL AND METHODS: To investigate the relationship between B7-H3 expression and the NK-cell function in ovarian cancer, human ovarian tumor tissues and cell lines were first examined the protein and mRNA expression of B7-H3 by quantitative real-time PCR (qRT-PCR), Immunohistochemistry and Western-blot assays. Then we established B7-H3 knockout cell lines and measured the cytotoxicity of NK cells on these cells by LDH release assay and Flow Cytometry. In addition, we analyzed B7-H3 in the regulation of glycolysis and glycolysis-related proteins by Glycolysis Stress Test, Glucose Consumption Assay and Western-blot. Moreover, luciferase reporter assay was used to confirm the directly regulation of miR-29c to B7-H3. Finally, we carried out in vivo experiments. RESULTS: We observed that tumor-expressed B7-H3 inhibits NK-cell function in vitro and in vivo, and is associated with glycolysis of ovarian cancer cell. Therapeutically, B7-H3 blockade prolonged the survival of SKOV3 tumor-bearing mice. In addition, miR-29c improved the anti-tumor efficacy of NK-cell by directly targeting B7-H3 in vitro were observed, but not in vivo. CONCLUSION: Our results demonstrate that miR-29c downregulates B7-H3 to inhibit NK-cell exhaustion and associated with glycolysis, which suggest that NK cells may be a new target of anti-B7-H3 therapy in ovarian cancer patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Deng M, Wu D, Zhang Y, et al. MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer. Gynecol Oncol. 2021. PMID: 33875234. doi:10.1016/j.ygyno.2021.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。